| |
Home »
News » 01/06 »
Cephalon signs double deal
Cephalon signs double deal
Date published: 12/01/2006
Cephalon and
Mylan Technologies have
signed two agreements to develop and commercialise pain and central nervous
system disorders products and to settle a patent infringement dispute. The
patent dispute centres on the sleep disorder drug Provigil
(modafinil).
Cephalon has granted Mylan a non-exclusive royalty-bearing
right to market and sell a generic version of Provigil in the US. The licence
will become effective in 2011. The company has made it clear this agreement
does not affect other ongoing lawsuits concerning patent infringement of
pharmaceutical compositions and methods of treatment with the form of modafinil
contained in Provigil.
Cephalon and Mylan have also got together for a
collaboration agreement over transdermal technology to address certain pain and
central nervous system disorders. The two firms will collaborate to create
branded transdermal products to develop and commercialise in exchange for
payment of milestones and ongoing royalties to Mylan based on sales.
Robert Coury, Mylan's vice chairman and CEO, said: "This type of
collaboration will leverage MTI's [Mylan Technologies Inc] state-of-the-art
technology and expertise and has the potential to allow Mylan to participate in
branded commercial opportunities without additional R&D net costs. "These
agreements are the latest in what we believe will be a series of branded
strategic alliances and further demonstrate MTI's position as partner of choice
for transdermal technology."
Financial details of neither agreement
were released. Mylan Technologies is a subsidiary of Mylan Laboratories.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|
